Combination of Pharmacophore Matching, 2D Similarity Search, and in Vitro Biological Assays in the Selection of Potential 5-HT6 Antagonists from Large Commercial Repositories

Chemical Biology and Drug Design

Volumn 86, Issue 4, 2015, Pages 864-880

  Dobi, Krisztina ^a   Flachner, Beáta ^a   Pukáncsik, Mária ^a   Máthé, Eniko ^a   Bognár, Melinda ^a   Szaszkõ, Mária ^a   Magyar, Csaba ^b   Hajdú, István ^a   Lorincz, Zsolt ^a   Simon, István ^b   Fülöp, Ferenc ^c   Cseh, Sándor ^a   Dormán, György ^a  

^a Targetex Kft   (Hungary)

^b INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^c UNIVERSITY OF SZEGED   (Hungary)

Author keywords

biological screening; combinatorial chemistry; drug discovery; G Protein coupled receptor; virtual screening

Indexed keywords

G PROTEIN COUPLED RECEPTOR; LIGAND; SEROTONIN ANTAGONIST; MOLECULAR LIBRARY; SEROTONIN 6 RECEPTOR; SEROTONIN RECEPTOR;

ANIMAL CELL; ARTICLE; BIOASSAY; COMPUTER MODEL; DATA BASE; DRUG SCREENING; HUMAN; IN VITRO STUDY; NONHUMAN; PHARMACOPHORE; PRIORITY JOURNAL; SCREENING; VALIDATION PROCESS; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DATABASE; DRUG DEVELOPMENT; METABOLISM; MOLECULAR LIBRARY; PHARMACOLOGY; PROCEDURES;

DATABASES, PHARMACEUTICAL; DRUG DISCOVERY; HUMANS; LIGANDS; MODELS, MOLECULAR; RECEPTORS, SEROTONIN; SEROTONIN ANTAGONISTS; SMALL MOLECULE LIBRARIES;

EID: 84942551614     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/cbdd.12563     Document Type: Article

References (55)

1. Holenz J., Pauwels P.J., Díaz J.L., Mercè R., Codony X., Buschmann H., (2006) Medicinal chemistry strategies to 5-HT(6) receptor ligands as potential cognitive enhancers and antiobesity agents. Drug Discov Today; 11: 283-299.
2. Heal D.J., Smith S.L., Fisas A., Codony X., Buschmann H., (2008) Selective 5-HT6 receptor ligands: progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disorders. Pharmacol Ther; 117: 207-231.
3. Hoyer D., Clarke D.E., Fozard J.R., Hartig P.R., Martin G.R., Mylecharane E.J., Saxena P.R., Humphrey P.P., (1994) International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). Pharmacol Rev; 46: 157-203.
4. Hoyer D., Martin G.R., (1996) Classification and nomenclature of 5-HT receptors: a comment on current issues. Behav Brain Res; 73: 263-268.
5. Woolley M.L., Marsden C.A., Fone K.C.F., (2004) 5-ht6 receptors. Curr Drug Targets CNS Neurol Disord; 3: 59-79.
6. Kohen R., Metcalf M.A., Khan N., Druck T., Huebner K., Lachowicz J.E., Meltzer H.Y., Sibley D.R., Roth B.L., Hamblin M.W., (1996) Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor. J Neurochem; 66: 47-56.
7. Messina D., Annesi G., Serra P., Nicoletti G., Pasqua A., Annesi F., Tomaino C., Cirò-Candiano I.C., Carrideo S., Caracciolo M., Spadafora P., Zappia M., Savettieri G., Quattrone A., (2002) Association of the 5-HT6 receptor gene polymorphism C267T with Parkinson's disease. Neurology; 58: 828-829.
8. Zhang J.Y., Nawoschik S., Kowal D., Smith D., Spangler T., Ochalski R., Schechter L., Dunlop J., (2003) Characterization of the 5-HT6 receptor coupled to Ca2+ signaling using an enabling chimeric G-protein. Eur J Pharmacol; 472: 33-38.
9. Sebben M., Ansanay H., Bockaert J., Dumuis A., (1994) 5-HT6 receptors positively coupled to adenylyl cyclase in striatal neurones in culture. NeuroReport; 5: 2553-2557.
10. Bonsi P., Cuomo D., Ding J., Sciamanna G., Ulrich S., Tscherter A., Bernardi G., Surmeier D.J., Pisani A., (2007) Endogenous serotonin excites striatal cholinergic interneurons via the activation of 5-HT 2C, 5-HT6, and 5-HT7 serotonin receptors: implications for extrapyramidal side effects of serotonin reuptake inhibitors. Neuropsychopharmacology; 32: 1840-1854.
11. Hebert L.E., Scherr P.A., Bienias J.L., Bennett D.A., Evans D.A., (2003) Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol; 60: 1119-1122.
12. Mount C., Downton C., (2006) Alzheimer disease: progress or profit? Nat Med; 12: 780-784.
13. Bromidge S.M., Brown A.M., Clarke S.E., Dodgson K., Gager T., Grassam H.L., Jeffrey P.M., Joiner G.F., King F.D., Middlemiss D.N., Moss S.F., Newman H., Riley G., Routledge C., Wyman P., (1999) 5-Chloro-N-(4-methoxy-3-piperazin-1-yl- phenyl)-3-methyl-2-benzothiophenesulfon- amide (SB-271046): a potent, selective, and orally bioavailable 5-HT6 receptor antagonist. J Med Chem; 42: 202-205.
14. Benhamú B., Martín-Fontecha M., Vázquez-Villa H., Pardo L., Lõpez-Rodríguez M.L., (2014) Serotonin 5-HT6 receptor antagonists for the treatment of cognitive deficiency in Alzheimer's disease. J Med Chem; 57: 7160-7181.
15. Garcia-Alloza M., Hirst W.D., Chen C.P.L., Lasheras B., Francis P.T., Ramírez M.J., (2004) Differential involvement of 5-HT(1B/1D) and 5-HT6 receptors in cognitive and non-cognitive symptoms in Alzheimer's disease. Neuropsychopharmacology; 29: 410-416.
16. Liu K.G., Robichaud A.J., (2009) 5-HT6 antagonists as potential treatment for cognitive dysfunction. Drug Dev Res; 70: 145-168.
17. Jorgensen W.L., (2004) The many roles of computation in drug discovery. Science; 303: 1813-1818.
18. Yang S., (2010) Pharmacophore modeling and applications in drug discovery: challenges and recent advances. Drug Discov Today; 15: 444-450.
19. Horvath D., (2011) Pharmacophore-based virtual screening. Methods Mol Biol; 672: 261-298.
20. Stahura F.L., Bajorath J., (2004) Virtual screening methods that complement HTS. Comb Chem High Throughput Screen; 7: 259-269.
21. Ma X.H., Zhu F., Liu X., Shi Z., Zhang J.X., Yang S.Y., Wei Y.Q., Chen Y.Z., (2012) Virtual screening methods as tools for drug lead discovery from large chemical libraries. Curr Med Chem; 19: 5562-5571.
22. Decornez H., Gulyás-Forrõ A., Papp A., Szabõ M., Sármay G., Hajdú I., Cseh S., Dormán G., Kitchen D.B., (2009) Design, selection, and evaluation of a general kinase-focused library. ChemMedChem; 4: 1273-1278.
23. Polgár T., Keseru G.M., (2011) Integration of virtual and high throughput screening in lead discovery settings. Comb Chem High Throughput Screen; 14: 889-897.
24. Willett P., (2006) Similarity-based virtual screening using 2D fingerprints. Drug Discov Today; 11: 1046-1053.
25. Johnson M.A., Maggiora G.M., eds. (1990) Concepts and Applications of Molecular Similarity. New York: John Wiley & Sons.
26. Khanna V., Ranganathan S., (2009) Physiochemical property space distribution among human metabolites, drugs and toxins. BMC Bioinformatics; 10 (Suppl. 15): S10.
27. Di L., Kerns E.H., Carter G.T., (2009) Drug-like property concepts in pharmaceutical design. Curr Pharm Des; 15: 2184-2194.
28. Lipinski C.A., Lombardo F., Dominy B.W., Feeney P.J., (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev; 46: 3-26.
29. Veber D.F., Johnson S.R., Cheng H., Smith B.R., Ward K.W., Kopple K.D., (2002) Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem; 45: 2615-2623.
30. Olah M.M., Bologa C.G., Oprea T.I., (2004) Strategies for compound selection. Curr Drug Discov Technol; 1: 211-220.
31. Morphy R., (2006) The influence of target family and functional activity on the physicochemical properties of pre-clinical compounds. J Med Chem; 49: 2969-2978.
32. Dobi K., Hajdú I., Flachner B., Fabõ G., Szaszkõ M., Bognár M., Magyar C., Simon I., Szisz D., Lorincz Z., Cseh S., Dorman Gy, (2014) Combination of 2D/3D ligand-based similarity search in rapid virtual screening from multimillion compound repositories. Selection and biological evaluation of potential PDE4 and PDE5 inhibitors. Molecules; 19: 7008-7039.
33. Tömöri T., Hajdú I., Barna L., Lorincz Z., Cseh S., Dormán G., (2012) Combining 2D and 3D in silico methods for rapid selection of potential PDE5 inhibitors from multimillion compounds' repositories: biological evaluation. Mol Divers; 16: 59-72.
34. Tanrikulu Y., Krüger B., Proschak E., (2013) The holistic integration of virtual screening in drug discovery. Drug Discov Today; 18: 358-364.
35. Wang H., Duffy R.A., Boykow G.C., Chackalamannil S., Madison V.S., (2008) Identification of novel cannabinoid CB1 receptor antagonists by using virtual screening with a pharmacophore model. J Med Chem; 51: 2439-2446.
36. Foudah A.I., Sallam A.A., Akl M.R., El Sayed K.A., (2014) Optimization, pharmacophore modeling and 3D-QSAR studies of sipholanes as breast cancer migration and proliferation inhibitors. Eur J Med Chem; 73: 310-324.
37. Flachner B., Tömöri T., Hajdú I., Dobi K., Lorincz Z., Cseh S., Dormán G., (2013) Rapid in silico selection of an MCHR1 antagonists' focused library from multi-million compounds' repositories: biological evaluation. Med Chem Res; 23: 1234-1247.
38. Tovar A., Eckert H., Bajorath J., (2007) Comparison of 2D fingerprint methods for multiple-template similarity searching on compound activity classes of increasing structural diversity. ChemMedChem; 2: 208-217.
39. Willett P., Winterman V., (1986) A comparison of some measures for the determination of inter-molecular structural similarity measures of inter-molecular structural similarity. Quant Struct-Act Rel; 5: 18-25.
40. Adams S., Glen R., (2006) Similarity metrics and descriptor spaces-which combinations to choose? QSAR Comb Sci; 25: 1133-1142.
41. Dixon S.L., Koehler R.T., (1999) The hidden component of size in two-dimensional fragment descriptors: side effects on sampling in bioactive libraries. J Med Chem; 42: 2887-2900.
42. Brock T.S., Pascal B., Nicholas I.C., (2008) Recent advances on the 5-HT5A, 5-HT6 and 5-HT7 receptors. Annu Rep Med Chem; 43: 25-42.
43. Kitson S.L., (2007) 5-hydroxytryptamine (5-HT) receptor ligands. Curr Pharm Des; 13: 2621-2637.
44. Button D., Brownstein M., (1993) Aequorin-expressing mammalian cell lines used to report Ca2+ mobilization. Cell Calcium; 14: 663-671.
45. Irwin J.J., Sterling T., Mysinger M.M., Bolstad E.S., Coleman R.G., (2005) ZINC: a free tool to discover chemistry for biology. J Chem Inf Model; 45: 177-182.
46. Bojarski A.J., (2006) Pharmacophore models for metabotropic 5-HT receptor ligands. Curr Top Med Chem; 6: 2005-2026.
47. Lõpez-Rodríguez M.L., Benhamú B., de la Fuente T., Sanz A., Pardo L., Campillo M., (2005) A three-dimensional pharmacophore model for 5-hydroxytryptamine6 (5-HT6) receptor antagonists. J Med Chem; 48: 4216-4219.
48. Ivachtchenko A.V., Golovina E.S., Kadieva M.G., Kysil V.M., Mitkin O.D., Tkachenko S.E., Okun I.M., (2011) Synthesis and structure-activity relationship (SAR) of (5,7-disubstituted 3-phenylsulfonyl-pyrazolo[1,5-a]pyrimidin-2-yl)-methylamines as potent serotonin 5-HT(6) receptor (5-HT(6)R) antagonists. J Med Chem; 54: 8161-8173.
49. Brini M., Marsault R., Bastianutto C., Alvarez J., Pozzan T., Rizzuto R., (1995) Transfected aequorin in the measurement of cytosolic Ca2+ concentration ([Ca2+]c). A critical evaluation. J Biol Chem; 270: 9896-9903.
50. Stables J., Green A., Marshall F., Fraser N., Knight E., Sautel M., Milligan G., Lee M., Rees S., (1997) A bioluminescent assay for agonist activity at potentially any G-protein-coupled receptor. Anal Biochem; 252: 115-126.
51. Mattsson C., Sonesson C., Sandahl A., Greiner H.E., Gassen M., Plaschke J., Leibrock J., Böttcher H., (2005) 2-Alkyl-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indoles as novel 5-HT6 receptor agonists. Bioorg Med Chem Lett; 15: 4230-4234.
52. Isaac M., Slassi A., Xin T., MacLean N., Wilson J., McCallum K., Wang H., Demchyshyn L., (2000) 6-Bicyclopiperazinyl-1-arylsulfonylindoles and 6-bicyclopiperidinyl-1-arylsulfonylindoles derivatives as novel, potent, and selective 5-HT6 receptor antagonists. Bioorg Med Chem Lett; 10: 1719-1721.
53. Dixon S.L., Smondyrev A.M., Knoll E.H., Rao S.N., Shaw D.E., Friesner R.A., (2006) PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results. J Comput Aided Mol Des; 20: 647-671.
54. Abad-Zapatero C., (2007) Ligand efficiency indices for effective drug discovery. Expert Opin Drug Discov; 2: 469-488.
55. Hopkins A.L., Keser G.M., Leeson P.D., Rees D.C., Reynolds C.H., (2014) The role of ligand efficiency metrics in drug discovery. Nat Rev Drug Discov; 13: 105-121.